Free Trial

Boston Scientific (BSX) Stock Price, News & Analysis

+0.26 (+0.34%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
3.19 million shs
Average Volume
6.33 million shs
Market Capitalization
$113.57 billion
P/E Ratio
Dividend Yield
Price Target

Boston Scientific MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.95 Rating Score
0.9% Downside
$76.70 Price Target
Short Interest
0.91% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.79mentions of Boston Scientific in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$5.94 M Sold Last Quarter
Proj. Earnings Growth
From $2.32 to $2.62 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.10 out of 5 stars

Medical Sector

154th out of 913 stocks

Surgical & Medical Instruments Industry

24th out of 100 stocks

BSX stock logo

About Boston Scientific Stock (NYSE:BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

BSX Stock Price History

BSX Stock News Headlines

Boston Scientific (NYSE:BSX) Raised to Buy at
See More Headlines
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
22 Analysts


Net Income
$1.59 billion
Pretax Margin


Sales & Book Value

Annual Sales
$14.24 billion
Cash Flow
$2.90 per share
Book Value
$13.33 per share


Outstanding Shares
Free Float
Market Cap
$113.57 billion

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained


Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • Boston Scientific Co. has shown consistent revenue growth over the past few quarters, indicating a strong financial performance.
  • The company's latest product innovations, such as the groundbreaking medical device for cardiac procedures, have received positive feedback from the medical community, potentially driving future sales.
  • Recent acquisitions by Boston Scientific Co. have expanded its market presence and diversified its product portfolio, reducing dependency on specific product lines.
  • Analysts predict a bullish trend for Boston Scientific Co. stock, with a target price higher than the current market value, presenting a potential opportunity for capital appreciation.
  • The company's focus on research and development ensures a pipeline of new products, enhancing competitiveness and long-term growth prospects.


Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • Market volatility and regulatory challenges in the healthcare sector could impact Boston Scientific Co.'s stock price, leading to short-term fluctuations.
  • Intense competition in the medical device industry may pressure profit margins and limit market share growth for Boston Scientific Co.
  • Fluctuations in foreign exchange rates could affect the company's international operations and financial performance, posing a risk to investors.
  • Concerns about healthcare policy changes or reimbursement rates could impact the demand for Boston Scientific Co.'s products, affecting revenue streams.
  • Any delays in product approvals or regulatory clearances could hinder the company's ability to bring new innovations to market, potentially impacting future earnings.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 8, 2024. Please send any questions or comments about these Boston Scientific pros and cons to

BSX Stock Analysis - Frequently Asked Questions

Should I buy or sell Boston Scientific stock right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last twelve months. There are currently 2 hold ratings, 19 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BSX shares.
View BSX analyst ratings
or view top-rated stocks.

What is Boston Scientific's stock price target for 2024?

22 Wall Street analysts have issued 1-year price targets for Boston Scientific's stock. Their BSX share price targets range from $60.00 to $95.00. On average, they anticipate the company's stock price to reach $76.70 in the next twelve months. This suggests that the stock has a possible downside of 0.9%.
View analysts price targets for BSX
or view top-rated stocks among Wall Street analysts.

How have BSX shares performed in 2024?

Boston Scientific's stock was trading at $57.81 at the start of the year. Since then, BSX shares have increased by 33.9% and is now trading at $77.41.
View the best growth stocks for 2024 here

Are investors shorting Boston Scientific?

Boston Scientific saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 13,380,000 shares, an increase of 8.5% from the May 15th total of 12,330,000 shares. Based on an average daily volume of 6,110,000 shares, the days-to-cover ratio is presently 2.2 days.
View Boston Scientific's Short Interest

When is Boston Scientific's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our BSX earnings forecast

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) announced its earnings results on Wednesday, April, 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.05. The medical equipment provider had revenue of $3.86 billion for the quarter, compared to analyst estimates of $3.68 billion. Boston Scientific had a net margin of 12.06% and a trailing twelve-month return on equity of 16.39%.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific issued an update on its second quarter 2024 earnings guidance on Wednesday, April, 24th. The company provided earnings per share (EPS) guidance of 0.570-0.590 for the period, compared to the consensus EPS estimate of 0.560. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $3.9 billion.

What is Michael F. Mahoney's approval rating as Boston Scientific's CEO?

947 employees have rated Boston Scientific Chief Executive Officer Michael F. Mahoney on Michael F. Mahoney has an approval rating of 98% among the company's employees. This puts Michael F. Mahoney in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), Walt Disney (DIS), Bank of America (BAC), Advanced Micro Devices (AMD), Visa (V) and Salesforce (CRM).

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.69%), Janus Henderson Group PLC (1.27%), Capital World Investors (1.09%), Bank of New York Mellon Corp (1.05%), Canada Pension Plan Investment Board (0.54%) and Lazard Asset Management LLC (0.51%). Insiders that own company stock include Arthur C Butcher, Charles J Dockendorff, Charles J Dockendorff, Daniel J Brennan, David A Pierce, David S Wichmann, Edward J Ludwig, Edward J Ludwig, Eric Francis Yves Thepaut, Ian T Meredith, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Jonathan Monson, Joseph Michael Fitzgerald, Meghan Scanlon, Michael F Mahoney, Michael F Mahoney, Nelda J Connors, Scott Olson, Vance R Brown and Wendy Carruthers.
View institutional ownership trends

How do I buy shares of Boston Scientific?

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Boston Scientific have any subsidiaries?
The following companies are subsidiares of Boston Scientific: 34 Biomedical Merger Corp., 9357-1867 Quebec Inc., Acurate Industria e Comercio Ltda., Advanced Bionics, Advanced Stent Technologies, American Medical Systems, American Medical Systems Europe B.V., Apama Medical, Apama Medical Inc., Asthmatx, Atritech, Augmenix, Augmenix Inc., Augmenix K.K., BSC International Medical Trading (Shanghai) Co. Ltd., BSC Medical Device Technology (Shanghai) Co. Ltd., BTG, BTG Australasia Pty Ltd, BTG Europe B.V., BTG IM Holdings Ltd., BTG International (Holdings) Limited, BTG International Asia Limited, BTG International Canada Inc., BTG International Germany GmbH, BTG International Healthcare Inc., BTG International Healthcare LLC, BTG International Healthcare Limited, BTG International Inc., BTG International Limited, BTG Limited, BTG Management Services Limited, BTG Medikal Limited Sirketi, Bard Electrophysiology, Barosense, Biocompatibles Inc., Biocompatibles International Limited, Biocompatibles UK Limited, Boston Scientific (Malaysia) Sdn. Bhd., Boston Scientific (South Africa) Proprietary Limited, Boston Scientific (Thailand) Ltd., Boston Scientific (UK) Limited, Boston Scientific AG, Boston Scientific Argentina S.A., Boston Scientific Asia Pacific Pte. Ltd., Boston Scientific Benelux NV, Boston Scientific Canada Limited, Boston Scientific Ceska republika s.r.o., Boston Scientific Chile SpA, Boston Scientific Colombia Limitada, Boston Scientific Comercial de Costa Rica BSCR S.R.L., Boston Scientific Far East B.V., Boston Scientific Gesellschaft m.b.H., Boston Scientific Group plc, Boston Scientific Hellas S.A., Boston Scientific Hong Kong Limited, Boston Scientific Iberica S.A., Boston Scientific India Private Limited, Boston Scientific International B.V., Boston Scientific International Finance Limited, Boston Scientific International S.A., Boston Scientific Israel Ltd., Boston Scientific Japan K.K., Boston Scientific Korea Co. Ltd., Boston Scientific Lebanon SAL, Boston Scientific Limited, Boston Scientific Ltd., Boston Scientific Medical Device, Boston Scientific Medical Device Limited, Boston Scientific Medizintechnik GmbH, Boston Scientific Middle East FZ-LLC, Boston Scientific Middle East SAL, Boston Scientific Nederland B.V., Boston Scientific Neuromodulation Corporation, Boston Scientific New Zealand Limited, Boston Scientific Nordic AB, Boston Scientific Peru S.A.C., Boston Scientific Philippines Inc., Boston Scientific Polska Sp. z o.o., Boston Scientific Portugal - Dispositivos Medicos Lda, Boston Scientific Pty Ltd, Boston Scientific Romania S.R.L., Boston Scientific S.A.S., Boston Scientific S.p.A., Boston Scientific Scimed, Boston Scientific Scimed Inc., Boston Scientific Services Private Limited, Boston Scientific TIP Gerecleri Limited Sirketi, Boston Scientific Technology & Engineering Services Private Limited, Boston Scientific Uruguay S.A., Boston Scientific Vietnam Company Limited, Boston Scientific de Costa Rica S.R.L., Boston Scientific de Mexico S.A. de C.V., Boston Scientific del Caribe Inc., Boston Scientific do Brasil Ltda., Bravo Bidco Limited, BridgePoint Medical, Cameron Health, Cardiac Pacemakers Inc., Cardiac Pathways Corp, Catheter Innovations, Claret Medical, Claret Medical Inc., Cosman Medical, Cosman Medical LLC, CryoCor, Cryterion Medical, Cryterion Medical Inc., Cryterion Medical Ireland Limited, EKOS LLC, EMcision, EMcision International Inc., EP Technologies, EP Technologies Inc., Electron Acquisition Corporation, EndoChoice, EndoChoice Holdings Inc., EndoChoice Inc., EndoChoice Innovation Center Ltd., EndoChoice Israel Ltd., Endotex, Enteric Medical Technologies, Galil Medical Inc., Galil Medical Ltd., Galil Medical UK Limited, Guidant, Guidant Delaware Holding Corporation, Guidant Europe NV, Guidant Puerto Rico B.V., Hong Kong Medtech Trading Limited, Intelect Medical, Millipede, Millipede Inc., NXT Merger Corp., Notebook Merger Sub Ltd., Novate Medical Limited, NxThera, NxThera Inc., PT Boston Scientific Indonesia, PneumRx GmbH, PneumRx LLC, PneumRx Liimited, Protherics Medicines Development B.V., Protherics Medicines Development Limited, Protherics UK Limited, Provensis Limited, RMI Acquisition Corp., Remon Medical Technologies, Rhythmia Medical, Robert S. Smith M.D. Inc., Roxwood Medical Inc., SNS Merger Corp, Sadra Medical, Sadra Medical Inc., Securus Medical Group, Securus Medical Group Inc., Special K Merger Corp., StarMedTec, Stream Enterprises LLC, Symetis, Symetis SA, Target Therapeutics, Target Therapeutics Inc., The LumenR Tissue Retractor System, Veniti, Veniti Inc., VertiFlex, Vertiflex Inc., Vessix Vascular, Xlumena, Zuma Investment Pty Ltd, iogyn, nVision Medical, and nVision Medical Corporation.
Read More
This page (NYSE:BSX) was last updated on 6/13/2024 by Staff

From Our Partners